Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Women in Science

Back to the Topic

Video clip: Angela reflects that building up a spin-off company can take several years.

So that's going back how many years…?

So we've been working with [Name] for nearly 15 years, yes so even, it was before I had my independent career.

So this is a disease, it's an orphan disease so it's not something that the pharmaceutical industry have been particularly concerned with, you know, trying to develop new treatments for it. There's a lot of biotech out there trying to develop new therapies but this was a fundamentally different way in which we thought we could actually tackle the disease.

So we're working in an orphan indication, we're also working on an idea for a mechanism for a drug that was really largely unprecedented. So we did some very early proof of concept work, 15 or so years ago, to show that it was indeed feasible in cells from a mouse or cells from a patient you are able to get these compounds to increase this protein that you wanted to replace dystrophin and that was the point at which this company which then became Summit span out of the university. We maintained an interest in that although Summit took those early compounds all the way through, as I say to the clinic, and it's now in that phase 2 trial, so fingers crossed. We'll know in the next 12 months or so whether that's going to affect the patients, I certainly hope we have a positive outcome in that trial.